EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial
On Mary 14, 2026, Edesa Biotech, Inc. (EDSA) announced financial results for the second quarter of fiscal year 2026 that ended March 31, 2026. The...
84 Views
EDSA: Strengthened Phase 3 ARDS Data Shows Significant Reduction in 28-Day Mortality
On February 24, 2026, Edesa Biotech, Inc. (EDSA) announced additional positive data from the company's Phase 3 study of EB05 (paridiprubart) in...
241 Views
EDSA: Gearing Up to Initiate Phase 2 Vitiligo Trial in Mid-2026
On December 12, 2025, Edesa Biotech, Inc. (EDSA) announced financial results for fiscal year 2025 that ended September 30, 2025 and provided a...
382 Views
EDSA: EB05 Reduces Risk of Death 25% in Phase 3 ARDS Trial
On October 28, 2025, Edesa Biotech, Inc. (EDSA) announced positive results from a Phase 3 clinical trial evaluating paridiprubart (EB05) as a...
526 Views
EDSA: EB06 Manufacturing to be Completed by End of 2025
On August 11, 2025, Edesa Biotech, Inc. (EDSA) announced financial results for the third quarter of fiscal year 2025 that ended June 30, 2025 and...
247 Views